Skip to main content

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group

Abstract

Background

Retroperitoneal soft tissue sarcomas (RPS) are rare tumors that include several well-defined histologic subtypes. Although surgery is the mainstay of curative therapy, no universally accepted recommendations concerning the best management have been developed to date. Optimization of the initial approach is critical for maximizing patient outcomes.

Methods

An RPS Trans-Atlantic Working Group was established in 2013. The primary aim was to evaluate the current evidence critically and to develop a consensus document on the approach to this difficult disease. The outcome applies to primary RPS that is nonvisceral in origin. The evaluation included sarcomas of major veins (inferior vena cava, renal vein, ovarian/testicular vein), undifferentiated pleomorphic sarcoma of the psoas, and ureteric leiomyosarcoma (LMS). It excluded desmoid, lipoma and angiomyolipoma, gastrointestinal stromal tumors, visceral sarcomas such as those arising from the gut or its mesentery, uterine LMS, prostatic sarcoma, paratesticular/spermatic cord sarcoma, Ewing’s sarcoma, alveolar/embryonal rhabdomyosarcoma, primitive peripheral neuro-ectodermal tumor, sarcoma arising from teratoma, carcinosarcoma, sarcomatoid carcinoma, clear cell sarcoma, radiation-induced sarcoma, paraganglioma, and malignant pheochromocytoma.

Results

Management of RPS was evaluated from diagnosis to follow-up, and a level of evidence was attributed to each statement. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the statements included in this article.

Conclusions

International collaboration is critical for adding to the current knowledge. A prospective registry will be set up.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Cormier JN, Gronchi A, Pollock RE. Soft tissue sarcomas. In: Brunicardi F, Andersen D, Billiar T, Dunn D, Hunter J, Matthews J, Pollock RE (eds) Schwartz’s principles of surgery. New York: McGraw-Hill; 2014.

    Google Scholar 

  2. 2.

    Lewis JJ, Leung D, Woodruff JM. Retroperitoneal soft-tissue sarcoma: analysis of 500 patients treated and followed at a single institution. Ann Surg. 1998;228:355–65.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  3. 3.

    Stoeckle E, Coindre JM, Bonvalot S, et al. Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer. 2001;92:359–68.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer. 2004;100:2448–55.

    PubMed  Article  Google Scholar 

  5. 5.

    Hassan I, Park SZ, Donohue JH, et al. Operative management of primary retroperitoneal sarcomas: a reappraisal of an institutional experience. Ann Surg. 2004; 239:244–50.

    PubMed Central  PubMed  Article  Google Scholar 

  6. 6.

    van Dalen T, Plooij JM, van Coevorden F, et al. Long-term prognosis of primary retroperitoneal soft tissue sarcoma. Eur J Surg Oncol. 2007;33:234–8.

    PubMed  Article  Google Scholar 

  7. 7.

    Lehnert T, Cardona S, Hinz U, et al. Primary and locally recurrent retroperitoneal soft-tissue sarcoma: local control and survival. Eur J Surg Oncol. 2009;35:986–93.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Anaya DA, Lahat G, Liu J, et al. Multifocality in retroperitoneal sarcoma: a prognostic factor critical to surgical decision making. Ann Surg. 2009;249:137–42.

    PubMed  Article  Google Scholar 

  9. 9.

    Strauss DC, Hayes AJ, Thway K, et al. Surgical management of primary retroperitoneal sarcoma. Br J Surg. 2010;101:520–3.

    Google Scholar 

  10. 10.

    Bonvalot S, Rivoire M, Castaing M, et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. J Clin Oncol. 2009;27:31–7.

    PubMed  Article  Google Scholar 

  11. 11.

    Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27:24–30.

  12. 12.

    Bonvalot S, Miceli R, Berselli M, et al. Aggressive surgery in retroperitoneal soft tissue sarcoma carried out at high-volume centers is safe and is associated with improved local control. Ann Surg Oncol. 2010;17:1507–14.

    PubMed  Article  Google Scholar 

  13. 13.

    Gronchi A, Miceli R, Colombo C, et al. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. Ann Oncol. 2012;23:1067–73.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Singer S, Antonescu CR, Riedel E, et al. Histologic subtype and margin of resection predict pattern of recurrence and survival for retroperitoneal liposarcoma. Ann Surg. 2003;238:358–70.

    PubMed Central  PubMed  Google Scholar 

  15. 15.

    Dalal KM, Kattan MW, Antonescu CR, et al. Subtype-specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.

    PubMed Central  PubMed  Google Scholar 

  16. 16.

    Canter RJ, Qin LX, Ferrone CR, et al. Why do patients with low-grade soft tissue sarcoma die? Ann Surg Oncol. 2008;15:3550–60.

    PubMed Central  PubMed  Article  Google Scholar 

  17. 17.

    http://clinicaltrials.gov/ct2/show/NCT01344018. Accessed 14 Feb 2014.

  18. 18.

    Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.

    PubMed  Article  Google Scholar 

  19. 19.

    Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012;13:1045–54.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Gronchi A, Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. Ann Surg Oncol. 2011;18: 2107–10.

    PubMed  Article  Google Scholar 

  21. 21.

    Gronchi A, Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? Ann Surg Oncol. 2013;20:2111–13.

    PubMed  Article  Google Scholar 

  22. 22.

    Dykewicz CA. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clin Infect Dis. 2001;33:139–44.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Gutierrez JC, Perez EA, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4,205 patients. Ann Surg. 2007;245:952–8.

    PubMed Central  PubMed  Article  Google Scholar 

  24. 24.

    Heudel PE, Cousin P, Lurkin A, et al. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhône-Alpes region. Int J Clin Oncol. 2014;19:744–52.

  25. 25.

    von Mehren M, Benjamin RS, Bui MM, et al. Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2012;10:951–60.

    Google Scholar 

  26. 26.

    ESMO/European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii92–9.

  27. 27.

    Miah AB, Hannay J, Benson C, et al. Optimal management of primary retroperitoneal sarcoma: an update. Expert Rev Anticancer Ther. 2014;14:565–79.

  28. 28.

    Strauss DC, Hayes AJ, Thomas JM. Preoperative core needle biopsy is safe and does not affect oncological outcome in retroperitoneal sarcoma. Poster HH, p. 112, CTOS 17th Annual Meeting, November 2012.

  29. 29.

    Lahat G, Madewell JE, Anaya DA, et al. Computed tomography scan-driven selection of treatment for retroperitoneal liposarcoma histologic subtypes. Cancer. 2009;115:1081–90.

    PubMed  Article  Google Scholar 

  30. 30.

    Gronchi A, Miceli R, Shurell E, et al. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center data sets. J Clin Oncol. 2013;31:1649–55.

    PubMed  Article  Google Scholar 

  31. 31.

    Toulmonde M, Bonvalot S, Méeus P, et al. Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors, and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol. 2014;25:735–42.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Bonvalot S, Raut CP, Pollock RE, et al. Technical considerations in surgery for retroperitoneal sarcomas: position paper from E-Surge, a master class in sarcoma surgery, and EORTC-STBSG. Ann Surg Oncol. 2012;19:2981–91.

    PubMed  Article  Google Scholar 

  33. 33.

    Pisters PW, O’Sullivan B. Retroperitoneal sarcomas: combined modality treatment approaches. Curr Opin Oncol. 2002;14:400–5.

    PubMed  Article  Google Scholar 

  34. 34.

    Gilbeau L, Kantor G, Stoeckle E, et al. Surgical resection and radiotherapy for primary retroperitoneal soft tissue sarcoma. Radiother Oncol. 2002;65:137–43.

    PubMed  Article  Google Scholar 

  35. 35.

    Pawlik TM, Pisters PW, Mikula L, et al. Long-term results of two prospective trials of preoperative external beam radiotherapy for localized intermediate- or high-grade retroperitoneal soft tissue sarcoma. Ann Surg Oncol. 2006;13:508–17.

    PubMed  Article  Google Scholar 

  36. 36.

    Feng M, Murphy J, Griffith KA, et al. Long-term outcomes after radiotherapy for retroperitoneal and deep truncal sarcoma. Int J Radiat Oncol Biol Phys. 2007;69:103–10.

    PubMed  Article  Google Scholar 

  37. 37.

    Ballo MT, Zagars GK, Pollock RE, et al. Retroperitoneal soft tissue sarcoma: an analysis of radiation and surgical treatment. Int J Radiat Oncol Biol Phys. 2007;67:158–63.

    PubMed  Article  Google Scholar 

  38. 38.

    Paryani NN, Zlotecki RA, Swanson EL, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012;82:1128–34.

    PubMed  Article  Google Scholar 

  39. 39.

    Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014. doi:10.1016/j.radonc.2013.10.041.

  40. 40.

    Pisters PW, Ballo MT, Fenstermacher MJ, et al. Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma. J Clin Oncol. 2003;21:3092–7.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Gronchi A, De Paoli A, Dani C, et al. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. Eur J Cancer. 2014;50:784–92.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Angele MK, Albertsmeier M, Prix NJ, et al. Effectiveness of regional hyperthermia with chemotherapy for high-risk retroperitoneal and abdominal soft-tissue sarcoma after complete surgical resection: a randomized phase-III multicenter study. Ann Surg. (in press).

  43. 43.

    Canter RJ, Qin LX, Maki RG, et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res. 2008;14:8191–7.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  44. 44.

    Saynak M, Bayir-Angin G, Kocak Z, et al. Recurrent solitary fibrous tumor of the pleura: significant response to radiotherapy. Med Oncol. 2010;27:45–8.

    PubMed  Article  Google Scholar 

  45. 45.

    Radaelli S, Stacchiotti S, Casali PG, et al. Emerging therapies for adult soft tissue sarcoma. Expert Rev Anticancer Ther. 2014;14:689–704.

  46. 46.

    Alektiar KM, Hu K, Anderson L, et al. High-dose-rate intraoperative radiation therapy (HDR-IORT) for retroperitoneal sarcomas. Int J Radiat Oncol Biol Phys. 2000;47:157–63.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Gieschen HL, Spiro IJ, Suit HD, et al. Long-term results of intraoperative electron beam radiotherapy for primary and recurrent retroperitoneal soft tissue sarcoma. Int J Radiat Oncol Biol Phys. 2001;50:127–31.

    CAS  PubMed  Article  Google Scholar 

  48. 48.

    Yoon SS, Chen YL, Kirsch DG, et al. Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas. Ann Surg Oncol. 2010;17:1515–29.

    PubMed Central  PubMed  Article  Google Scholar 

  49. 49.

    McBride SM, Raut CP, Lapidus M, et al. Loco-regional recurrence after pre-operative radiation therapy for retroperitoneal sarcoma: adverse impact of multifocal disease and potential implications of dose escalation. Ann Surg Oncol. 2013;20:2140–7.

    PubMed  Article  Google Scholar 

  50. 50.

    Roeder F, Schulz-Ertner D, Nikoghosyan AV, et al. A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma. BMC Cancer. 2012;12:287.

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  51. 51.

    Le Péchoux C, Musat E, Baey C, et al. Should adjuvant radiotherapy be administered in addition to front-line aggressive surgery (FAS) in patients with primary retroperitoneal sarcoma? Ann Oncol. 2013;24:832–7.

    PubMed  Article  Google Scholar 

  52. 52.

    Paryani NN1, Zlotecki RA, Swanson EL, et al. Multimodality local therapy for retroperitoneal sarcoma. Int J Radiat Oncol Biol Phys. 2012;82:1128–34.

  53. 53.

    Mohindra P, Neuman HB, Kozak KR. The role of radiation in retroperitoneal sarcomas. Curr Treat Options Oncol. 2013;14:425–41.

    PubMed Central  PubMed  Article  Google Scholar 

  54. 54.

    Smith MJ, Ridgway PF, Catton CN, et al. Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: long-term results of a prospective trial. Radiother Oncol. 2014;110:165–71.

    PubMed  Article  Google Scholar 

  55. 55.

    Dziewirski W1, Rutkowski P, Nowecki ZI, et al. Surgery combined with intraoperative brachytherapy in the treatment of retroperitoneal sarcomas. Ann Surg Oncol. 2006;13:245–52.

Download references

Conflict of interest

There are no conflicts of interest.

Author information

Affiliations

Consortia

Additional information

Correspondence to: Alessandro Gronchi

Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, e-mail: alessandro.gronchi@istitutotumori.mi.it

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Trans-Atlantic RPS Working Group. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group. Ann Surg Oncol 22, 256–263 (2015). https://doi.org/10.1245/s10434-014-3965-2

Download citation

Keywords

  • Sarcoma
  • Gastrointestinal Stromal Tumor
  • Liposarcoma
  • Paraganglioma
  • Clear Cell Sarcoma